16 September 2022 - If granted by the European Commission, Veklury will become the first and only authorised anti-viral treatment for paediatric patients under 12 years of age in the European Union.

Gilead Sciences today announced that the CHMP of the EMA adopted a positive opinion to extend the indication of Veklury (remdesivir) for the treatment of paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19 and paediatric patients (4 weeks of age and older and weighing at least 3 kg) with SARS-CoV-2 with pneumonia who require supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at the start of treatment).

Read Gilead press release